MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-31-2023
Ayala Pharmaceuticals Operating Cycle 2011-2026 | AYLA
Annual Operating Cycle Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.7 | 35.5 | 67 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 67 | 35.5 | 54.7 |
Quarterly Operating Cycle Ayala Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 196 | 1.08 K | 63.6 | - | 95 | 65.8 | 39.8 | - | 94.4 | 59.5 | 52.4 | - | 50.6 | 50.2 | 80.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.08 K | 39.8 | 161 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amphastar Pharmaceuticals
AMPH
|
237 | $ 21.75 | 1.59 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.91 | 1.61 % | $ 6.69 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
332 | $ 22.29 | 1.5 % | $ 3.69 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.1 | 0.37 % | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 23.2 | -0.26 % | $ 2.95 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
129 | $ 1.42 | -1.39 % | $ 378 M | Britain |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
127 | - | - | $ 546 M | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.72 | -0.29 % | $ 115 M | USA |
 |
BioXcel Therapeutics
BTAI
|
1.66 K | $ 1.07 | 0.94 % | $ 13.1 M | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 1.95 | 1.83 % | $ 405 M | USA |
 |
CASI Pharmaceuticals
CASI
|
135 | - | - | $ 35.4 M | USA |